Research programme: mRNA based gene therapies - GreenLight Biosciences
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator GreenLight Biosciences
- Class Antianaemics; Gene therapies
- Mechanism of Action Gene modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Sickle-cell-anaemia in USA (Parenteral)
- 15 Sep 2020 mRNA based gene therapies - GreenLight Biosciences is available for licensing as of 15 Sep 2020. https://www.greenlightbiosciences.com/contact/
- 15 Sep 2020 Early research in Sickle cell anaemia in USA (Parenteral)